<p>Arcus Biosciences, Inc.（纽约证券交易所代码：RCUS - 获取免费报告）首席财务官罗伯特·戈尔茨二世于 12 月 17 日（星期三）出售了 5,960 股该股票。股票的平均售价为 22.16 美元，总交易额为 132,073.60 美元。出售后，首席财务官持有 74,476 股公司股票，价值 1,650,388.16 美元。这笔交易代表其持股减少了 7.41%。该出售在向美国证券交易委员会提交的文件中披露，相关文件可通过此链接访问。</p>
<p>获取 <strong>Arcus Biosciences</strong> 的提醒：</p>
<h2>Arcus Biosciences 股票表现</h2>
<ul>
<li>从落后者到领头羊：小型股正在崛起</li>
</ul>
<p>RCUS 股票在周四交易中下跌 0.26 美元，跌至 22.02 美元。该公司的交易量为 1,175,874 股，而其平均交易量为 1,200,446 股。该公司的 50 日移动平均价格为 20.82 美元，200 日移动平均价格为 13.98 美元。公司快速比率为 3.65，流动比率为 3.65，债务与股本比率为 0.22。该公司的市值为 23.8 亿美元，市盈率为-6.40，贝塔值为 0.75。Arcus Biosciences, Inc.的 1 年最低价为 6.50 美元，1 年最高价为 26.40 美元。</p>
<p>Arcus Biosciences（纽约证券交易所代码：RCUS - 获取免费报告）最后一次公布财报是在 10 月 28 日（星期二）。公司报告本季度每股收益为（1.27 美元），超出市场共识预期的（1.33 美元）0.06 美元。公司本季度的收入为 2600 万美元，而市场共识预期为 1989 万美元。Arcus Biosciences 的股本回报率为-68.17%，净利润率为-136.40%。公司的收入同比下降了 45.8%。去年同期，该公司每股收益为（1.00 美元）。分析师平均预计 Arcus Biosciences, Inc.在当前年度的每股收益为-3.15 美元。</p>
<h2>Arcus Biosciences 的机构交易</h2>
<ul>
<li>MarketBeat 周回顾 – 7/10 - 7/14</li>
</ul>
<p>对冲基金和其他机构投资者最近买卖了该公司的股票。先锋集团在第一季度将其在 Arcus Biosciences 的持股增加了 24.1%。先锋集团现在拥有 6687800 股公司股票，价值 52499000 美元，此前在该期间内又购买了 1298584 股。查尔斯·施瓦布投资管理公司在第一季度将其在 Arcus Biosciences 的持股增加了 23.2%。查尔斯·施瓦布投资管理公司现在拥有 714002 股公司股票，价值 5605000 美元，此前又购买了 134379 股。马里兰州退休与养老金系统在第一季度将其在 Arcus Biosciences 的持股增加了 10.9%。马里兰州退休与养老金系统现在拥有 20202 股公司股票，价值 159000 美元，此前在上个季度又购买了 1986 股。瑞士国家银行在第一季度将其在 Arcus Biosciences 的持股增加了 35.9%。瑞士国家银行现在拥有 133596 股公司股票，价值 1049000 美元，此前又购买了 35300 股。最后，景顺有限公司在第一季度将其在 Arcus Biosciences 的持股增加了 24.5%。景顺有限公司现在拥有 254024 股公司股票，价值 1994000 美元，此前在上个季度又收购了 50037 股。92.89% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>华尔街分析师预测增长</h2>
<p>RCUS 已成为多份研究分析师报告的主题。HC Wainwright 在 12 月 12 日的报告中将 Arcus Biosciences 的目标价格从 28.00 美元上调至 32.00 美元，并给予该股票 “买入” 评级。美国银行在 11 月 28 日的研究报告中将 Arcus Biosciences 的目标价格从 17.00 美元上调至 26.00 美元，并给予该股票 “中性” 评级。Wedbush 在 10 月 29 日的报告中设定了 Arcus Biosciences 的目标价格为 35.00 美元，并给予该股票 “跑赢大盘” 评级。瑞银集团在周一的研究报告中重申了对 Arcus Biosciences 股票的 “买入” 评级。最后，Wall Street Zen 在周日的研究报告中将 Arcus Biosciences 的评级从 “卖出” 上调至 “持有”。八位投资分析师对该股票给予了 “买入” 评级，两位给予了 “持有” 评级，一位给予了 “卖出” 评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “适度买入”，平均目标价格为 28.89 美元。</p>
<ul>
<li>吉利德通过在 AlloVir 和 Arcus 的股份扩大生物技术足迹</li>
</ul>
<p><strong>查看我们关于 RCUS 的最新报告</strong></p>
<h2>Arcus Biosciences 公司简介</h2>
<p>（获取免费报告）</p>
<p>Arcus Biosciences, Inc.是一家临床阶段的生物制药公司，在美国开发和商业化癌症疗法。公司的管线产品包括 Domvanalimab，一种抗 TIGIT 抗体，目前处于 2 期和 3 期临床试验；以及 AB308，一种研究性抗 TIGIT 单克隆抗体，目前处于 1b 期临床试验，研究对象为晚期实体瘤和血液恶性肿瘤患者。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 Arcus Biosciences</li>
<li>股票评级和建议：理解分析师评级</li>
<li>博通股票暴跌 20%——但华尔街认为它将飙升至 500 美元</li>
<li>如何计算退休收入：MarketBeat 的计算器</li>
<li>忘掉芯片：AI 反弹的四个工业投资机会</li>
<li>交易暂停的解释</li>
<li>MongoDB 可能创下新高——但你需要迅速行动</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVJDVVM?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVJDVVM"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 Arcus Biosciences 吗？</h2>
<p>在考虑 Arcus Biosciences 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Arcus Biosciences 并不在名单上。</p>
<p>虽然 Arcus Biosciences 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

RCUS

<p>Arcus Biosciences 的首席财务官 Robert Goeltz II 出售了 5,960 股，交易金额为 132,073.60 美元，减少了 7.41% 的持股比例。出售后，他持有 74,476 股，价值 165 万美元。该交易已在 SEC 备案中披露。Arcus Biosciences 的市值为 23.8 亿美元，最近的财报业绩超出预期。机构投资者持有 92.89% 的股份。分析师们的评级不一，有些分析师上调了目标价格</p>

<p>Arcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) CFO Robert Goeltz II sold 5,960 shares of the stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $22.16, for a total transaction of $132,073.60. Following the sale, the chief financial officer owned 74,476 shares of the company's stock, valued at $1,650,388.16. This trade represents a 7.41% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.</p>
<div class="lb-trans"><p>Arcus Biosciences, Inc.（纽约证券交易所代码：RCUS - 获取免费报告）首席财务官罗伯特·戈尔茨二世于 12 月 17 日（星期三）出售了 5,960 股该股票。股票的平均售价为 22.16 美元，总交易额为 132,073.60 美元。出售后，首席财务官持有 74,476 股公司股票，价值 1,650,388.16 美元。这笔交易代表其持股减少了 7.41%。该出售在向美国证券交易委员会提交的文件中披露，相关文件可通过此链接访问。</p>
</div><p>Get <strong>Arcus Biosciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Arcus Biosciences</strong> 的提醒：</p>
</div><h2>Arcus Biosciences Stock Performance</h2>
<div class="lb-trans"><h2>Arcus Biosciences 股票表现</h2>
</div><ul>
<li>From laggards to leaders: Small caps on the rise</li>
</ul>
<div class="lb-trans"><ul>
<li>从落后者到领头羊：小型股正在崛起</li>
</ul>
</div><p>RCUS stock traded down $0.26 during trading on Thursday, hitting $22.02. The company had a trading volume of 1,175,874 shares, compared to its average volume of 1,200,446. The firm has a 50-day moving average price of $20.82 and a 200-day moving average price of $13.98. The company has a quick ratio of 3.65, a current ratio of 3.65 and a debt-to-equity ratio of 0.22. The firm has a market cap of $2.38 billion, a PE ratio of -6.40 and a beta of 0.75. Arcus Biosciences, Inc. has a 1-year low of $6.50 and a 1-year high of $26.40.</p>
<div class="lb-trans"><p>RCUS 股票在周四交易中下跌 0.26 美元，跌至 22.02 美元。该公司的交易量为 1,175,874 股，而其平均交易量为 1,200,446 股。该公司的 50 日移动平均价格为 20.82 美元，200 日移动平均价格为 13.98 美元。公司快速比率为 3.65，流动比率为 3.65，债务与股本比率为 0.22。该公司的市值为 23.8 亿美元，市盈率为-6.40，贝塔值为 0.75。Arcus Biosciences, Inc.的 1 年最低价为 6.50 美元，1 年最高价为 26.40 美元。</p>
</div><p>Arcus Biosciences (NYSE:RCUS - Get Free Report) last announced its earnings results on Tuesday, October 28th. The company reported ($1.27) earnings per share for the quarter, beating the consensus estimate of ($1.33) by $0.06. The company had revenue of $26.00 million for the quarter, compared to the consensus estimate of $19.89 million. Arcus Biosciences had a negative return on equity of 68.17% and a negative net margin of 136.40%.The company's revenue was down 45.8% on a year-over-year basis. During the same period last year, the business posted ($1.00) EPS. On average, analysts expect that Arcus Biosciences, Inc. will post -3.15 earnings per share for the current year.</p>
<div class="lb-trans"><p>Arcus Biosciences（纽约证券交易所代码：RCUS - 获取免费报告）最后一次公布财报是在 10 月 28 日（星期二）。公司报告本季度每股收益为（1.27 美元），超出市场共识预期的（1.33 美元）0.06 美元。公司本季度的收入为 2600 万美元，而市场共识预期为 1989 万美元。Arcus Biosciences 的股本回报率为-68.17%，净利润率为-136.40%。公司的收入同比下降了 45.8%。去年同期，该公司每股收益为（1.00 美元）。分析师平均预计 Arcus Biosciences, Inc.在当前年度的每股收益为-3.15 美元。</p>
</div><h2>Institutional Trading of Arcus Biosciences</h2>
<div class="lb-trans"><h2>Arcus Biosciences 的机构交易</h2>
</div><ul>
<li>MarketBeat Week in Review – 7/10 - 7/14</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周回顾 – 7/10 - 7/14</li>
</ul>
</div><p>Hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. grew its position in shares of Arcus Biosciences by 24.1% in the first quarter. Vanguard Group Inc. now owns 6,687,800 shares of the company's stock valued at $52,499,000 after purchasing an additional 1,298,584 shares during the period. Charles Schwab Investment Management Inc. lifted its position in Arcus Biosciences by 23.2% during the first quarter. Charles Schwab Investment Management Inc. now owns 714,002 shares of the company's stock worth $5,605,000 after buying an additional 134,379 shares during the period. Maryland State Retirement &amp; Pension System boosted its stake in Arcus Biosciences by 10.9% in the 1st quarter. Maryland State Retirement &amp; Pension System now owns 20,202 shares of the company's stock worth $159,000 after buying an additional 1,986 shares during the last quarter. Swiss National Bank grew its holdings in Arcus Biosciences by 35.9% in the 1st quarter. Swiss National Bank now owns 133,596 shares of the company's stock valued at $1,049,000 after buying an additional 35,300 shares during the period. Finally, Invesco Ltd. increased its stake in shares of Arcus Biosciences by 24.5% during the 1st quarter. Invesco Ltd. now owns 254,024 shares of the company's stock valued at $1,994,000 after acquiring an additional 50,037 shares during the last quarter. 92.89% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>对冲基金和其他机构投资者最近买卖了该公司的股票。先锋集团在第一季度将其在 Arcus Biosciences 的持股增加了 24.1%。先锋集团现在拥有 6687800 股公司股票，价值 52499000 美元，此前在该期间内又购买了 1298584 股。查尔斯·施瓦布投资管理公司在第一季度将其在 Arcus Biosciences 的持股增加了 23.2%。查尔斯·施瓦布投资管理公司现在拥有 714002 股公司股票，价值 5605000 美元，此前又购买了 134379 股。马里兰州退休与养老金系统在第一季度将其在 Arcus Biosciences 的持股增加了 10.9%。马里兰州退休与养老金系统现在拥有 20202 股公司股票，价值 159000 美元，此前在上个季度又购买了 1986 股。瑞士国家银行在第一季度将其在 Arcus Biosciences 的持股增加了 35.9%。瑞士国家银行现在拥有 133596 股公司股票，价值 1049000 美元，此前又购买了 35300 股。最后，景顺有限公司在第一季度将其在 Arcus Biosciences 的持股增加了 24.5%。景顺有限公司现在拥有 254024 股公司股票，价值 1994000 美元，此前在上个季度又收购了 50037 股。92.89% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>RCUS has been the topic of a number of research analyst reports. HC Wainwright boosted their price objective on shares of Arcus Biosciences from $28.00 to $32.00 and gave the stock a &#34;buy&#34; rating in a report on Friday, December 12th. Bank of America boosted their price target on Arcus Biosciences from $17.00 to $26.00 and gave the stock a &#34;neutral&#34; rating in a research note on Friday, November 28th. Wedbush set a $35.00 price target on Arcus Biosciences and gave the stock an &#34;outperform&#34; rating in a report on Wednesday, October 29th. UBS Group reaffirmed a &#34;buy&#34; rating on shares of Arcus Biosciences in a research note on Monday. Finally, Wall Street Zen upgraded Arcus Biosciences from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Sunday. Eight investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of &#34;Moderate Buy&#34; and an average target price of $28.89.</p>
<div class="lb-trans"><p>RCUS 已成为多份研究分析师报告的主题。HC Wainwright 在 12 月 12 日的报告中将 Arcus Biosciences 的目标价格从 28.00 美元上调至 32.00 美元，并给予该股票 “买入” 评级。美国银行在 11 月 28 日的研究报告中将 Arcus Biosciences 的目标价格从 17.00 美元上调至 26.00 美元，并给予该股票 “中性” 评级。Wedbush 在 10 月 29 日的报告中设定了 Arcus Biosciences 的目标价格为 35.00 美元，并给予该股票 “跑赢大盘” 评级。瑞银集团在周一的研究报告中重申了对 Arcus Biosciences 股票的 “买入” 评级。最后，Wall Street Zen 在周日的研究报告中将 Arcus Biosciences 的评级从 “卖出” 上调至 “持有”。八位投资分析师对该股票给予了 “买入” 评级，两位给予了 “持有” 评级，一位给予了 “卖出” 评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “适度买入”，平均目标价格为 28.89 美元。</p>
</div><ul>
<li>Gilead Boosts Biotech Footprint With Stakes In AlloVir And Arcus</li>
</ul>
<div class="lb-trans"><ul>
<li>吉利德通过在 AlloVir 和 Arcus 的股份扩大生物技术足迹</li>
</ul>
</div><p><strong>Check Out Our Latest Report on RCUS</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 RCUS 的最新报告</strong></p>
</div><h2>Arcus Biosciences Company Profile</h2>
<div class="lb-trans"><h2>Arcus Biosciences 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.</p>
<div class="lb-trans"><p>Arcus Biosciences, Inc.是一家临床阶段的生物制药公司，在美国开发和商业化癌症疗法。公司的管线产品包括 Domvanalimab，一种抗 TIGIT 抗体，目前处于 2 期和 3 期临床试验；以及 AB308，一种研究性抗 TIGIT 单克隆抗体，目前处于 1b 期临床试验，研究对象为晚期实体瘤和血液恶性肿瘤患者。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Arcus Biosciences</li>
<li>Stock Ratings and Recommendations: Understanding Analyst Ratings</li>
<li>Broadcom Stock Crashes 20%—But Wall Street Sees It Soaring to $500</li>
<li>How to Calculate Retirement Income: MarketBeat’s Calculator</li>
<li>Forget the Chips: 4 Industrial Plays for the AI Rebound</li>
<li>Trading Halts Explained</li>
<li>MongoDB Could Hit Record Highs—But You’ll Need to Move Fast</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Arcus Biosciences</li>
<li>股票评级和建议：理解分析师评级</li>
<li>博通股票暴跌 20%——但华尔街认为它将飙升至 500 美元</li>
<li>如何计算退休收入：MarketBeat 的计算器</li>
<li>忘掉芯片：AI 反弹的四个工业投资机会</li>
<li>交易暂停的解释</li>
<li>MongoDB 可能创下新高——但你需要迅速行动</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVJDVVM" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NYSE&amp;Symbol=RCUS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Arcus Biosciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Arcus Biosciences 吗？</h2>
</div><p>Before you consider Arcus Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Arcus Biosciences 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arcus Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Arcus Biosciences 并不在名单上。</p>
</div><p>While Arcus Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Arcus Biosciences 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Arcus Biosciences (NYSE:RCUS) 的首席财务官出售了价值 132,073.60 美元的股票